RheumatoidDiseases & ConditionsDrugsDrugs PregnancyRisksRisks PregnancyArthritisBone And JointRheumatoid ArthritisConditionsLupusGeneral HealthPrescription DrugsDrug Use During PregnancyPregnancyPregnancy RisksConditionDiseases
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Nov. 2, 2012 (HealthDay News) -- A new study suggests that pregnant women with the autoimmune disease lupus may have a twofold increased risk of preeclampsia, a dangerous condition characterized by high blood pressure and protein in the urine.
Preeclampsia can lead to serious health problems such as seizure, stroke and organ failure and cause the death of the mother and/or baby.
The researchers also found that the use of disease-modifying antirheumatic drugs (DMARDs) during pregnancy was associated with a statistically insignificant increased risk of preeclampsia. These medications are used to treat lupus and other autoimmune diseases such as rheumatoid arthritis, although their use during pregnancy is rare.
The slightly higher risk associated with antirheumatic drugs could be explained by the severity of autoimmune disease among users, according to the study, which was published in the November issue of the journal Arthritis Care & Research. This class of medications includes methotrexate (brand names Rheumatrex and Trexall), hydroxychloroquine (Plaquenil, Quineprox), etanercept (Enbrel) and adalimumab (Humira).
Understanding how their use affects women with autoimmune disease is important, especially during pregnancy, lead author Kristin Palmsten, of the Harvard School of Public Health, said in a journal news release.
Palmsten and her colleagues looked at data on nearly 307,000 pregnancies among almost 225,000 women in the province of British Columbia, Canada.
"Our findings uphold previous evidence, showing that women with [lupus] had twice the risk of developing preeclampsia," she said. "The statistically non-significant increase in preeclampsia risk found for DMARDs was reduced when we more fully accounted for the potential effect of the autoimmune diseases, suggesting that the underlying disease or severity of the disease was likely contributing to the increased risk of preeclampsia among DMARD users."
Further research is needed to confirm the findings, and studies should focus on use of DMARDs and preeclampsia in women with specific autoimmune diseases, the researchers concluded.
The new study found a link between lupus and preeclampsia. It did not prove a cause-and-effect relationship.
The Preeclampsia Foundation has more about preeclampsia.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on June 04, 2022
Read this Next
Other Trending Articles